Table 1

Characteristics of the patients

Total number, n431
Age, years64.1±11.5
Sex (female), n (%)399 (92.6)
Disease duration, years16.7±10.4
Stage (I/II/III/IV), n (%)87/152/51/141
(20.2/35.3/11.8/32.7)
28-tender joint count0.38±1.03
28-swollen joint count0.54±1.09
History of surgery, n (%)71 (16.5)
ESR, mm/h16.6±12.9
CRP, mg/dL0.22±0.48
RF positive, n (%)331 (76.8)
RF, IU/mL125.9±255.8
anti-CCP antibody positive, n (%)355 (82.4)
anti-CCP antibody, U/mL243.5±357.2
MTX use, n (%)329 (76.3)
MTX dose, mg6.03±4.32
MTX hold, n (%)48 (14.6)
PSL use, n (%)184 (42.7)
PSL dose, mg1.38±1.90
Biologics/JAK inhibitors, n (%)133 (30.9)
TNF-α inhibitors86 (20.0)
IL-6 inhibitors29 (6.7)
CTLA-4-Ig5 (1.2)
JAK inhibitors13 (3.0)
  • Values are mean±SD or number (%) of patients.

  • CCP, cyclic citrullinated peptide; CRP, C reactive protein; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ESR, erythrocyte sedimentation rate; IL, interleukin; JAK, Janus kinase; MTX, methotrexate; PSL, prednisolone; RF, rheumatoid factor; TNF, tumor necrosis factor.